Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04990076
Other study ID # s62497
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 11, 2020
Est. completion date March 30, 2024

Study information

Verified date July 2021
Source Universitaire Ziekenhuizen Leuven
Contact Christine De Bruyn, MD
Phone +32 16 345125
Email christine.debruyn@uzleuven.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main objective is to evaluate the diagnostic accuracy of the MUSA terms and definitions, as defined in the paper by Van den Bosch T, Dueholm M, ea. in 2015, to differentiate between different types of myometrial lesions of more than 1 cm. The primary aim is the diagnostic accuracy of the MUSA terms and definitions and the secondary aim the development of a prediction model.


Description:

Primary aim: Diagnostic accuracy of the MUSA terms and definitions Every patient planned for hysterectomy for myometrial pathology (e.g. benign fibroid, benign adenomyoma or malignant uterine sarcoma) will undergo a systematic preoperative ultrasound scan. Around 50 ultrasound characteristics (described in Addendum 1) will be assess as to diagnostic accuracy as predictors (Prospective evaluation of MUSA terms and definitions). Figure 1 shows the different histological endpoint with expected prevalence in our study population and table 1 further differentiate those histological endpoints. The estimation for sarcomas is based on preliminary and unpublished results from an ongoing prospective study led by prof dr Antonia Testa from the Università Cattolica di Sacro Cuore Largo Agostino Gemelli in Rome showing an incidence of 4.9% for uterine sarcomas amongst women with a myometrial lesion referred to their tertiary center (Antonia Testa, personal communication). Secondary aim: Development of prediction model The Secondary aim is to build predictive models to differentiate between benign myometrial lesions (e.g. adenomyosis and fibroid) and malignant myometrial lesion (e.g. uterine sarcoma). Because of the small number of cases with malignant myometrial lesion (expected to be 5% of the study population or around 75 women), we will limit the number of variables to be tested in order to avoid overfitting. Based on current literature, we preselected following characteristics for development of a prediction model: - Outer contour: regular of irregular - Echogenicity of uterine lesion: uniform (homogeneous) or non-uniform (mixed) - Colour score: 1 to 4 - Presence of central necrosis - Maximal diameter of the lesion (in mm) - Presence of acoustic shadows


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date March 30, 2024
Est. primary completion date March 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: Consecutive patients planned to undergo hysterectomy for myometrial pathology of more then 1cm (e.g. fibroid, focal adenomyosis, uterine sarcoma). Exclusion Criteria: - Patient's refusal - Age < 18 years - Polymyomatous uterus - Myometrial lesion with a diameter less then 10mm - Patients currently treated for another cancer - Patients with ovarian pathology, endometrial pathology of cervical pathology - Power morcellation

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Hysterectomy
Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.

Locations

Country Name City State
Belgium UZ Leuven Leuven

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

References & Publications (2)

Ludovisi M, Moro F, Pasciuto T, Di Noi S, Giunchi S, Savelli L, Pascual MA, Sladkevicius P, Alcazar JL, Franchi D, Mancari R, Moruzzi MC, Jurkovic D, Chiappa V, Guerriero S, Exacoustos C, Epstein E, Frühauf F, Fischerova D, Fruscio R, Ciccarone F, Zannoni GF, Scambia G, Valentin L, Testa AC. Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma. Ultrasound Obstet Gynecol. 2019 Nov;54(5):676-687. doi: 10.1002/uog.20270. Epub 2019 Oct 7. — View Citation

Van den Bosch T, Dueholm M, Leone FP, Valentin L, Rasmussen CK, Votino A, Van Schoubroeck D, Landolfo C, Installé AJ, Guerriero S, Exacoustos C, Gordts S, Benacerraf B, D'Hooghe T, De Moor B, Brölmann H, Goldstein S, Epstein E, Bourne T, Timmerman D. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015 Sep;46(3):284-98. doi: 10.1002/uog.14806. Epub 2015 Aug 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of the MUSA terms and definitions Around 50 ultrasound characteristics will be assess as to diagnostic accuracy as predictors (Prospective evaluation of MUSA terms and definitions). 4 years
Secondary Development of prediction model predictive models to differentiate between benign myometrial lesions (e.g. adenomyosis and fibroid) and malignant myometrial lesion (e.g. uterine sarcoma). 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Active, not recruiting NCT06114758 - Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
Not yet recruiting NCT05932082 - The Impact of Myomectomy on IVF Outcomes N/A
Not yet recruiting NCT05967936 - Paracervical Block Versus Transcervical Block in Outpatient Procedural Hysteroscopy N/A
Recruiting NCT04748978 - OPPIuM Technique and Myolysis With Diode Laser Dwls N/A
Recruiting NCT05271981 - Fertility After Uterine Artery Embolization
Completed NCT05025410 - Remimazolam and Remifentanil Without Neuromuscular Blocking Agent
Recruiting NCT03483142 - the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Phase 3
Completed NCT03533907 - Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.
Completed NCT05811286 - The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study N/A
Not yet recruiting NCT03570879 - Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens.
Not yet recruiting NCT04364581 - Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions Phase 4
Recruiting NCT06067971 - Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2) N/A
Recruiting NCT06325501 - Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy Phase 3
Completed NCT05761418 - Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy Phase 3
Recruiting NCT04311073 - Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies Phase 3
Active, not recruiting NCT05930769 - Retrospective Study on the Evaluation of the Impact of Augmented Reality Usage in Gynecological Laparoscopy on Patients Operated Between 2017 and 2021 (ImpactRA)
Recruiting NCT03550703 - Open Label Immunotherapy of Myoma Phase 2
Completed NCT04482959 - Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy Phase 4
Not yet recruiting NCT04030273 - Prevalence of Intrauterine Adhesions After Abdominal Myomectomy